Interference Testing
Overview
Authors
Affiliations
* Interference occurs when a substance or process falsely alters an assay result. * Interferences are classified as endogenous or exogenous. Endogenous interference originates from substances present in the patient's own specimen. Exogenous interferences are substances introduced into the patient's specimen. * To perform interference studies, proper planning is required. * Interference from haemolysis, icterus and lipaemia are most frequently studied. Haemolysis affects more analytes than does any other type of interference. * Protein interferences are most often associated with paraproteins and predominantly with IgM or IgG and rarely with IgA. * Drug interference may be due to the parent drug, metabolite(s) or additives in the drug preparation. * Collection tube components can affect determination of analytes. * Carryover interference typically occurs when analyte from a high concentration sample (or reagent) is incompletely removed by the analytical system's washing process, whether probe, mixer or cuvette washing. * Immunoassay interferences are most commonly due to antibodies (generally polyclonal). They may be autoantibodies (e.g. in thyroid disease) or heterophile antibodies that predominantly interfere in two-site immunometric (sandwich) assays, forming a bridge between capture and detection antibodies. * Determining if interference is significant requires deviation limits from the original result. * Once interferences are identified during method evaluation or in general use, there is a need to establish procedures for handling affected results as part of the quality system.
Elevated Aβ aggregates in feces from Alzheimer's disease patients: a proof-of-concept study.
Pils M, Dybala A, Schaffrath A, Rehn F, Kutzsche J, Blomeke L Alzheimers Res Ther. 2024; 16(1):223.
PMID: 39402637 PMC: 11472473. DOI: 10.1186/s13195-024-01597-3.
Yu Y, Zhang X, Lin K Pract Lab Med. 2024; 40:e00414.
PMID: 38939102 PMC: 11208942. DOI: 10.1016/j.plabm.2024.e00414.
Mitigation of errors on an FDA-approved platform for cytomegalovirus viral load assay.
Youn J, Walker L, Carlson S, Soutar C, Frank K, Zelazny A J Clin Microbiol. 2024; 62(7):e0041624.
PMID: 38842311 PMC: 11250505. DOI: 10.1128/jcm.00416-24.
Xu X, Xu Y, Liang S J Clin Lab Anal. 2024; 38(10):e25045.
PMID: 38822626 PMC: 11211672. DOI: 10.1002/jcla.25045.
Lee J, Seo J, Lee K, Roh E, Yun Y, Lee Y Pract Lab Med. 2024; 38:e00347.
PMID: 38188654 PMC: 10770599. DOI: 10.1016/j.plabm.2023.e00347.